Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate rheumatoid arthritis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 25 - Nov - 2021
Body System:
Red
UPADACITINIB prolonged-release tablets (RINVOQ®▼) for treating moderate rheumatoid arthritis

The Pan Mersey Area Prescribing Committee recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ®▼), by specialists only, for treating moderate rheumatoid arthritis in accordance with NICE TA744.